The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy (Q47237809)

12 January 2018

title

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy (English)

1 reference

12 January 2018

1 reference

1 reference

2

S Loibl

1 reference

12 January 2018

7

I Ray-Coquard

1 reference

12 January 2018

author name string

L C Hanker

1

1 reference

12 January 2018

N Burchardi

3

1 reference

12 January 2018

J Pfisterer

4

1 reference

12 January 2018

W Meier

5

1 reference

12 January 2018

E Pujade-Lauraine

6

1 reference

12 January 2018

J Sehouli

8

1 reference

12 January 2018

P Harter

9

1 reference

12 January 2018

A du Bois

10

1 reference

12 January 2018

AGO and GINECO study group

11

1 reference

12 January 2018

publication date

21 August 2012

1 reference

12 January 2018

published in

Annals of Oncology

1 reference

12 January 2018

volume

23

1 reference

12 January 2018

issue

10

1 reference

12 January 2018

page(s)

2605-2612

1 reference

12 January 2018

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gyna

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Pharmaceutical management of ovarian cancer : current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Attitudes to chemotherapy in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Treatment preferences in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS203

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS203

1 reference

12 January 2018

1 reference

12 January 2018